IntelGenx’s Rizafilm Receives the US FDA’s Approval for the Treatment of Acute Migraine
Shots:
- The US FDA has approved the NDA of Rizafilm VersaFilm (US market name for Rizaport), an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraine
- The approval was based on results from a bioequivalence study evaluating Rizafilm vs the US reference Maxalt-MTL and the EU reference Maxalt-Lingua in 30 healthy volunteers which showed that Rizaport was bioequivalent to the US reference Maxalt-MTL and the EU reference Maxalt-Lingua
- Under the Dec 2018 agreement, IntelGenx collaborated with Gensco for the exclusive commercialization of Rizafilm in the US. Additionally, Rizafilm is expected to be commercially available in the US shortly
Ref: Globenewswire | Image: Intelgenx
Related News:- WAT Medical Reports Results of HeadaTerm TENS Therapy in a Clinical Study to Treat Acute Migraine
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
